The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
CALGB 50801 (Alliance): PET adapted therapy in bulky stage I/II classic Hodgkin lymphoma (cHL).
 
Ann S. LaCasce
Consulting or Advisory Role - Bristol-Myers Squibb; Forty Seven; Humanigen; Seagen
Speakers' Bureau - Research to Practice
Research Funding - Celgene (Inst); Forty Seven (Inst); Sanofi (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - Up to Date royalties
 
Travis Dockter
No Relationships to Disclose
 
Amy S. Ruppert
Consulting or Advisory Role - Telios
 
Lale Kostakoglu
Honoraria - Novartis
Consulting or Advisory Role - BeiGene; ImaginAb; Roche/Genentech
Travel, Accommodations, Expenses - Roche
 
Heiko Schöder
No Relationships to Disclose
 
Eric D. Hsi
Honoraria - Celgene; Jazz Pharmaceuticals; Seagen
Consulting or Advisory Role - Miltenyi Biotec
Research Funding - Abbvie (Inst); Cellerant Therapeutics (Inst); Lilly (Inst)
 
Jeffrey A Bogart
Stock and Other Ownership Interests - Cardan Robotics; Verve Medical
 
Bruce D. Cheson
Consulting or Advisory Role - Abbvie; Celgene; Epizyme; Gilead Sciences; Karyopharm Therapeutics; Morphosys; Parexel; Pharmacyclics/Janssen; SymBio Pharmaceuticals; TG Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); Seagen (Inst); TG Therapeutics (Inst); Trillium Therapeutics (Inst)
Travel, Accommodations, Expenses - SymBio Pharmaceuticals
 
Nina D. Wagner-Johnston
Consulting or Advisory Role - ADC Therapeutics; Bayer; Calibr; Gilead Sciences; Regeneron; Verastem
Research Funding - Acerta Pharma (Inst); ADC Therapeutics (Inst); Astex Pharmaceuticals (Inst); Genentech (Inst); Juno Therapeutics (Inst); Merck (Inst); Novartis/Pfizer (Inst); Regeneron (Inst)
 
Jeremy S. Abramson
Consulting or Advisory Role - Abbvie; Alimera Sciences; Bristol-Myers Squibb; C4 Therapeutics; Celgene; EMD Serono; Genentech; Janssen; Karyopharm Therapeutics; Kite, a Gilead company; MorphoSys; Novartis
Research Funding - AI Therapeutics (Inst); Celgene (Inst); Seagen (Inst)
 
Kami J. Maddocks
Honoraria - ADC Therapeutics; BMS; Celgene; Genmab; Karyopharm Therapeutics; Kite, a Gilead company; MorphoSys; Pharmacyclics; Seagen
Research Funding - Bristol-Myers Squibb; Merck; Pharmacyclics
 
John Paul Leonard
Consulting or Advisory Role - Abbvie; ADC Therapeutics; Akcea Therapeutics; AstraZeneca; Bayer; Bayer; Bristol-Myers Squibb; Celgene; Epizyme; Genentech/Roche; Genmab; Gilead Sciences; Incyte; Karyopharm Therapeutics; MEI Pharma; Merck; Miltenyi Biotec; Morphosys; Nordic Nanovector; Nordic Nanovector; Regeneron; Sandoz; Sutro Biopharma
Research Funding - Alliance for Clinical Trials in Oncology (Inst); Celgene (Inst); Epizyme (Inst); Janssen Oncology (Inst); National Cancer Institute (Inst); Pfizer (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - BeiGene
 
Nancy L. Bartlett
Consulting or Advisory Role - Acerta Pharma; ADC Therapeutics; BTG; Roche/Genentech; Seagen
Research Funding - ADC Therapeutics (Inst); Affimed Therapeutics (Inst); Autolus (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Forty Seven (Inst); Immune Design (Inst); Janssen (Inst); Kite, a Gilead company (Inst); Merck (Inst); Millennium (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche/Genentech (Inst); Seagen (Inst)